As of October 30, 2015, Zeltia SA was acquired by Pharma Mar, S.A.U. Zeltia, S.A. operates in the chemical and biopharmaceutical sectors in Spain and internationally. The company operates through Biopharmaceuticals and Consumer Chemicals segments. The Biopharmaceuticals segment researches, develops, and markets antitumor drugs; develops and markets diagnosis kits; and develops therapies based on reducing or silencing gene expression. This segments products include Yondeli, a marketed product for the treatment of ovarian cancer and soft tissue sarcoma; Aplidi, which is in Phase III trials for the treatment of multiple myeloma, as well as for T cell lymphoma; PM1183, which has completed Phase IIb trials for the treatment of ovarian cancer; and PM184 that is in Phase I trials for the treatment of solid tumors, as well as ISYL040012, which is in Phase IIB clinical trials for the treatment of glaucoma. The Consumer Chemicals segment produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and related products. Further, the company provides services for treating and protecting wood, and repairing and preserving structures, as well as insect control and disinfection services. Zeltia, S.A. was founded in 1939 and is based in Madrid, Spain.